Evaluation of WGc-043 Injection in Advanced Solid Tumors: Phase I Study

NCT ID: NCT07028047

Last Updated: 2025-06-19

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 64 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-06-23
• Study Completion Date: 2028-06-30

Brief Summary

Epstein-Barr virus (EBV) is an important tumor-associated virus. In 1997, the World Health Organization (WHO) officially classified EBV as a Group 1 carcinogen, as it is implicated in the pathogenesis of various epithelial malignancies and multiple types of lymphomas. Epithelial malignancies associated with EBV infection include nasopharyngeal carcinoma, gastric cancer, colorectal cancer, breast cancer, cervical cancer, prostate cancer, and oral cancer, among others. Currently, optimal therapeutic strategies for EBV-associated solid tumors remain lacking, particularly in patients with recurrent, metastatic, or refractory disease. Furthermore, although EBV infection plays a significant role in the development and progression of EBV-positive tumors and may influence patient prognosis, there are currently no precision therapeutic approaches specifically targeting EBV-positive lymphomas. Thus, treatment options for this patient population warrant further attention.

WGc-043 injection is a therapeutic tumor vaccine based on messenger RNA (mRNA) targeting tumor-specific antigens expressed in EBV-positive tumors. This Phase I clinical trial aims to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of WGc-043 in patients with advanced EBV-positive malignant solid tumors, thereby providing a scientific basis for subsequent clinical development.

Conditions

Advanced EBV-positive Malignant Solid Tumors

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

WGc-043 Injection, Dose 1

Group Type: EXPERIMENTAL

WGc-043 Injection

Intervention Type: BIOLOGICAL

WGc-043 Injection, intramuscular injection

WGc-043 Injection, Dose 2

Group Type: EXPERIMENTAL

WGc-043 Injection

Intervention Type: BIOLOGICAL

WGc-043 Injection, intramuscular injection

WGc-043 Injection, Dose 3

Group Type: EXPERIMENTAL

WGc-043 Injection

Intervention Type: BIOLOGICAL

WGc-043 Injection, intramuscular injection

WGc-043 Injection, Dose 4

Group Type: EXPERIMENTAL

WGc-043 Injection

Intervention Type: BIOLOGICAL

WGc-043 Injection, intramuscular injection

WGc-043 Injection, Extended dosage

Group Type: EXPERIMENTAL

WGc-043 Injection

Intervention Type: BIOLOGICAL

WGc-043 Injection, intramuscular injection

Interventions

WGc-043 Injection

WGc-043 Injection, intramuscular injection

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Male or female patients aged ≥18 years at the time of screening;

2. Histologically or cytologically confirmed locally recurrent or metastatic EBV-positive solid tumors that are not amenable to curative treatment;

3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;

4. Estimated life expectancy of ≥3 months;

5. At least one measurable lesion; previously irradiated lesions cannot be considered as target lesions unless there is evidence of significant progression;

6. Adequate major organ function, with organ function parameters meeting the criteria specified in the protocol;

7. Women of childbearing potential (WOCBP) or male subjects must have no plans for pregnancy during the study and must agree to use effective contraception (including one or more non-pharmacologic contraceptive methods or complete abstinence from heterosexual intercourse) or safety measures during the trial and for 6 months after discontinuation of treatment;

8. Ability to understand and voluntarily sign the written informed consent form prior to participation in the trial;

9. Ability to communicate effectively with the investigator and comply with the protocol requirements throughout the trial.

Exclusion Criteria

1. Patients with a history of other malignancies, except for those with a history of skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, carcinoma in situ of the cervix, gastrointestinal mucosal carcinoma, or other malignancies deemed by the investigator to be eligible for inclusion, provided that these cancers have been cured and have not recurred within 5 years prior to screening.

2. Patients with symptomatic central nervous system (CNS) metastases or leptomeningeal metastases, or those with evidence indicating that CNS or leptomeningeal metastases are not well-controlled, as judged by the investigator to be unsuitable for inclusion.

3. Patients with known uncontrolled cardiac symptoms or diseases, such as: New York Heart Association (NYHA) Class II or higher heart failure, unstable angina, myocardial infarction within the past 6 months, or clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention.

4. Any active autoimmune disease or a history of autoimmune disease.

5. Any uncontrolled clinical condition or other major medical illness that, in the judgment of the investigator, may interfere with the ability to provide informed consent, confound the interpretation of trial results, pose a risk to the patient's participation in the trial, or otherwise affect the achievement of trial objectives-including, but not limited to, uncontrolled pleural effusion, pericardial effusion, or ascites as determined by the investigator.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sun Yat-sen University

OTHER

Sponsor Role: lead

Responsible Party

Hai-Qiang Mai,MD,PhD

Assistant Dean and Director of Nasopharyngeal Department

Responsibility Role: PRINCIPAL_INVESTIGATOR

Other Identifiers

WGc-043-002

Identifier Type: -

Identifier Source: org_study_id